Gail Dutton

2 days ago | genengnews.com | Gail Dutton

Home Topics Bioprocessing Make Bioprocesses More Efficient by Making Them Less Complex Credit: Koldoy Chris/Getty Images Credit: Koldoy Chris/Getty Images “The best way to make things efficient and repeatable is to make them less complex.”That’s the opinion of Josh Ludwig, global commercial director at ScaleReady, and the guiding principle of lean manufacturing. For biopharma entrepreneurs, it’s never too early to take that message to heart.

2 weeks ago | genengnews.com | Gail Dutton

Home Topics Bioprocessing Fresh Hotspots ID’d for More Productive CHO Cell Lines Adherent Chinese hamster ovary (CHO) cells in cell culture flask (phase contrast microscopic view) [User: Alcibiades, Public domain, via Wikimedia Commons] Credit: Alcibiades/ Wikimedia Commons Although Chinese hamster ovary (CHO) cells have dominated therapeutic protein expression systems for decades, biomanufacturers still must deal with their inconsistent expression levels and varying productivity.

1 month ago | genengnews.com | Gail Dutton

Sizeable differences in gene expression means and ratios—based solely upon where genes are located on a plasmid (gene syntax)—have been discovered by researchers at Dartmouth College. This new understanding will help biomanufacturers to design more effective plasmids and genetic circuits and thereby enable more precise measurements of promoter activity, more accurate gene expression, and more predictable engineered systems.

1 month ago | genengnews.com | Gail Dutton

Home Topics Cancer National Commission Outlines Six Ways to Turbocharge U.S. Biotech Innovation Against the... Credit: Ipopba/Getty Images Credit: Ipopba/Getty Images Unless the U.S. acts rapidly now, China will almost inevitably become the world’s biotechnology superpower. The consequences for the world could be insurmountable.

1 month ago | genengnews.com | Gail Dutton

Large unmet needs for autoimmune disease therapeutics remain. For many patients, including approximately 25% of those with graft versus host disease (GvHD), existing therapeutics are inadequate. The outlook for better ones, though, is increasingly hopeful. In December, the U.S. Food & Drug Administration (FDA), in a first, approved a mesenchymal stem cell (MSC) therapeutic for children and adolescents with steroid-refractory acute GvHD.